Prothymosin alpha 1 effects in vitro on chemotaxis, cytotoxicity and oxidative response of neutrophils from melanoma, colorectal and breast tumor patients.
Immunoregulatory effects of thymic peptides on functions of polymorphonuclear leukocytes (PMNs) are poorly investigated. We studied the effects of prothymosin alpha 1 (Pro alpha 1) on PMNs from patients with colorectal tumors, breast tumors and melanoma (total n = 37) in comparison with healthy donors (n = 18), with respect to chemotaxis, cytotoxicity against HCT-116 colon tumor cells, oxidative response (chemiluminescence reaction) as well as expression of surface marker molecules. We found that Pro alpha 1 was equally effective in stimulating the chemotactic activity of PMNs from tumor patients and healthy donors (43% increase). PMNs from tumor patients, especially with breast tumor, showed a significant enhancement of cytotoxicity against the tumor target cells in comparison with healthy donors. With respect to the PMNs cytotoxicity, only about 50% of the colorectal tumor patients and healthy donors responded to Pro alpha 1 and FMLP. As to the oxidative response of PMNs, elevated levels were found only among colorectal tumor patients. Pro alpha 1 significantly increased the oxidative response in breast and colorectal tumor patients by 55% and 25%, respectively. Pro alpha 1 decreased the expression of CD16 on PMNs of healthy donors, but not that of CD11a, CD11b, CD11c, CD13, CD14, CD15 and CD32. Therefore, we suggest, that Pro alpha 1 may improve some PMN functions of tumor patients, associated with the proposed role in host-tumor interaction.
Heidecke
H
H
Dep. Biochemie, Molekularbiologie und Biotechnologie, Freie Universität Berlin, Germany.
Eckert
K
K
Schulze-Forster
K
K
Maurer
H R
HR
D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000097:blood*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005260:Female; D006801:Humans; D008163:Luminescent Measurements; D016177:Macrophage-1 Antigen / Q000096:biosynthesis; D008297:Male; D008545:Melanoma / Q000097:blood*; D008875:Middle Aged; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology / Q000502:physiology*; D011498:Protein Precursors / Q000494:pharmacology*; D017382:Reactive Oxygen Species / Q000378:metabolism*; D017452:Receptors, IgG / Q000096:biosynthesis; D013947:Thymosin / Q000031:analogs & derivatives* / Q000494:pharmacology
D016177:Macrophage-1 Antigen; D011498:Protein Precursors; D017382:Reactive Oxygen Species; D017452:Receptors, IgG; C040782:prothymosin alpha; D009240:N-Formylmethionine Leucyl-Phenylalanine; D013947:Thymosin